{
  "symbol": "MRK",
  "year": 2022,
  "Period": "Y2022",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1896,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.092
  },
  "top_positive": [
    {
      "sent": "Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements.",
      "score": 0.9774
    },
    {
      "sent": "Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements.",
      "score": 0.9774
    },
    {
      "sent": "Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements.",
      "score": 0.9774
    }
  ],
  "top_negative": [
    {
      "sent": "21 Table o f Contents Phase 2 Phase 3 (Phase 3 entry date) Under Review Cancer MK-0482 (2) Non-Small-Cell Lung MK-1026 (nemtabrutinib) Hematological Malignancies MK-1308 (quavonlimab) (2) Non-Small-Cell Lung MK-1308A (quavonlimab+pembrolizumab) Advanced Solid Tumors Colorectal Hepatocellular Melanoma Small-Cell-Lung MK-2140 (zilovertamab vedotin) Breast Hematological Malignancies Non-Small-Cell Lung MK-3475 Keytruda Advanced Solid Tumors MK-4280 (favezelimab) (2) Hematological Malignancies Non-Small-Cell Lung MK-4280A (favezelimab+pembrolizumab) Renal Cell Small-Cell Lung MK-4830 (2) Non-Small-Cell Lung Renal Cell Small-Cell Lung MK-5890 (2) Non-Small-Cell Lung Small-Cell Lung MK-6440 (ladiratuzumab vedotin) (1)(3) Breast Esophageal Gastric Head and Neck Melanoma Non-Small-Cell Lung Prostate Small-Cell Lung MK-6482 Welireg (3) Biliary Colorectal Hepatocellular Pancreatic Rare cancers Von Hippel-Lindau Disease-Associated Tumors (EU) MK-7119 Tukysa (1) Advanced Solid Tumors Biliary Bladder Cervical Colorectal Endometrial Gastric Non-Small-Cell Lung MK-7339 Lynparza (1)(3) Advanced Solid Tumors MK-7684 (vibostolimab) (2) Melanoma MK-7684A (vibostolimab+pembrolizumab) Biliary Breast Cervical Endometrial Esophageal Head and Neck Hematological Malignancies Hepatocellular Prostate MK-7902 Lenvima (1)(2) Biliary Glioblastoma Pancreatic Prostate Small-Cell Lung V937 Breast Cutaneous Squamous Cell Head and Neck Melanoma Solid Tumors Cardiovascular MK-2060 Chikungunya Virus Vaccine V184 HIV-1 Infection MK-8591B (islatravir+MK-8507) (4) MK-8591D (islatravir+lenacapavir) (1)(4) Nonalcoholic Steatohepatitis (NASH) MK-3655 MK-6024 Overgrowth Syndrome MK-7075 (miransertib) Pneumococcal Vaccine Adult V116 Pulmonary Arterial Hypertension MK-5475 Schizophrenia MK-8189 Treatment Resistant Depression MK-1942 Antiviral COVID-19 MK-4482 (molnupiravir) (May 2021) (1)(5) (U.S) Cancer MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-3475 Keytruda Biliary (September 2019) Cutaneous Squamous Cell (August 2019) (EU) Gastric (May 2015) (EU) Hepatocellular (May 2016) (EU) Mesothelioma (May 2018) Ovarian (December 2018) Prostate (May 2019) Small-Cell Lung (May 2017) MK-3475 (pembrolizumab subcutaneous) Non-Small-Cell Lung (August 2021) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) MK-6482 Welireg (3) Renal Cell (February 2020) MK-7119 Tukysa (1) Breast (October 2019) MK-7339 Lynparza (1)(3) Colorectal (August 2020) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Non-Small-Cell Lung (April 2021) MK-7902 Lenvima (1)(2) Colorectal (April 2021) Esophageal (July 2021) Gastric (December 2020) Head and Neck (February 2020) Melanoma (March 2019) Non-Small-Cell Lung (March 2019) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (4) HIV-1 Prevention MK-8591 (islatravir) (February 2021) (4) Pulmonary Arterial Hypertension MK-7962 (sotatercept) (January 2021) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) New Molecular Entities/Vaccines Antiviral COVID-19 MK-4482 (molnupiravir) (1) (EU) Cough MK-7264 (gefapixant) (U.S.) (6) (EU) Pneumococcal Vaccine Adult V114 (JPN) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    Adjuvant Treatment of  Stage IIB or IIC Melanoma (KEYNOTE-716) (EU) \u2022    Adjuvent Renal Cell Cancer (KEYNOTE-564) (JPN) \u2022    MSI-H or dMMR Endometrial Cancer (KEYNOTE-158) (U.S.) \u2022 MSI-H or dMMR Six Tumor Basket (KEYNOTE-158) (EU) \u2022    High-Risk Early-Stage Triple-Negative Breast Cancer (KEYNOTE-522) (EU) (JPN) \u2022    Tumor Mutational Burden-High (KEYNOTE-158) (JPN) \u2022    Cervical Cancer (KEYNOTE-826) (EU) (JPN) MK-7339 Lynparza (1) \u2022 BRCA -Mutated HER2-Negative Adjuvant Breast Cancer (OlympiA) (U.S.) (EU) \u2022 First-Line Metastatic Prostate Cancer (PROpel) (EU) MK-7902 Lenvima (1)(2) \u2022    First-Line Metastatic Hepatocellular Carcinoma (KEYNOTE-524) (U.S.) (7) \u2022    Advanced Unresectable Renal Cell Carcinoma (KEYNOTE-581) (JPN) (8) Footnotes: (1) Being developed in a collaboration.",
      "score": -0.9902
    },
    {
      "sent": "Certain of the products within the Company\u2019s franchises are as follows: Oncology Keytruda (pembrolizumab), the Company\u2019s anti-PD-1 (programmed death receptor-1) therapy, as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin Lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors), including MSI-H/dMMR colorectal cancer (CRC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer.",
      "score": -0.9858
    },
    {
      "sent": "Certain of the products within the Company\u2019s franchises are as follows: Oncology Keytruda (pembrolizumab), the Company\u2019s anti-PD-1 (programmed death receptor-1) therapy, as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin Lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors), including MSI-H/dMMR colorectal cancer (CRC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer.",
      "score": -0.9858
    }
  ],
  "forward_snippets": [
    "Merck\u2019s existing research pipeline programs continue to be owned and developed within Merck as planned.",
    "Merck\u2019s existing research pipeline programs continue to be owned and developed within Merck as planned.",
    "Merck\u2019s existing research pipeline programs continue to be owned and developed within Merck as planned.",
    "Merck\u2019s existing research pipeline programs continue to be owned and developed within Merck as planned.",
    "The rule provides comprehensive guidance on the calculation of AMP and Best Price, two metrics used to determine the rebates drug manufacturers are required to pay to state Medicaid programs."
  ]
}